Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

NCT02993523 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02993523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02993523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 2, 2017
Completion date
June 15, 2026
Enrollment
443 (actual)
Sites
172

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)